Skip Ribbon Commands
Skip to main content
Sign In
Cell Therapy Technologies
Enabling Next-Generation Cancer Treatments

Cell-based immunotherapy is currently at the forefront in the development of new treatments for serious diseases. For example, genetically modified autologous T-cells expressing chimeric antigen receptors (CAR) are generating sustained remissions for certain indications.1 Terumo BCT is proud to be a source of cell collection, expansion and separation technologies used in the production process for these potentially groundbreaking and lifesaving therapies.

Cell Collection

A quality apheresis collection is often the critical first step in the development of today's innovative immunotherapy treatments. Discover the Spectra Optia® Apheresis System and how it delivers high target cell collection with low non-target cell contamination, driving consistency and reproducibility. All backed by Terumo BCT's more than 30 years of experience in apheresis collection technology.

Cell Separation

The Elutra® Cell Separation System provides a standardized and consistent method for separating cell populations, making it well-suited for the enrichment of lymphocytes prior to isolation and expansion for T-cell therapies. The Elutra system offers greater than 65 percent recovery of both monocytes and lymphocytes, as well as greater than 75 percent purity.2

Cell Expansion

The Quantum® Cell Expansion System provides a solution for expansion of cells used in adoptive transfer therapies, including promising work in the area of T-cell therapies. The Quantum system has also been used to produce viral vectors, including lentivirus, and to support other areas of cancer research, such as the expansion of stable tumor lines and ex vivo maturation of dendritic cells.3

Read about lentiviral vector production at the UC Davis Institute for Regenerative Cures

Read about maturation of dendritic cells in the Quantum system

Customers are responsible for validating the use of the Quantum system to expand cells for their intended therapy.
Customers are responsible for validating the use of the Elutra system to separate cells for their intended therapy.
1Maude S, et al., "Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia." New England Journal of Medicine 2014; 371: 1507–1517.
2Powell DJ, et al., "Efficient Clinical-Scale Enrichment of Lymphocytes for Use in Adoptive Immunotherapy Using a Modified Counterflow Centrifugal Elutriation Program." Cytotherapy 2009; 11 (7): 923–935.
3Startz T, et al., "Maturation of Dendritic Cells From CD14+ Monocytes in an Automated Functionally Closed Hollow Fiber Bioreactor System." September 2014, Terumo BCT part number 306650243A.